What are the factors that affect the effectiveness of rapamycin, an mTORC1 inhibitor and anti-cancer agent? Specifically, we simulate acute and chronic administration of rapamycin, and seek to answer the question: Do rapamycin and PRAS40, both of which inhibit mTORC1, interact and produce nonlinear effects? One might expect that together, rapamycin and PRAS40 may produce more than the sum of individual effects. The gene discussed is AKT1S1; the disease is cancer.